November 26, 2014
US biotech major Amgen Inc. will terminate all clinical studies of rilotumumab for the treatment of advanced gastric cancer including the PIII RILOMET-2 program conducted in Japan and other Asian countries. Rilotumumab has been codeveloped by Astellas Pharma and its...read more